Harvest Portfolios Group Inc. Has $61.90 Million Stock Position in Medtronic PLC $MDT

Harvest Portfolios Group Inc. cut its stake in shares of Medtronic PLC (NYSE:MDT) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 649,942 shares of the medical technology company’s stock after selling 16,221 shares during the period. Medtronic makes up approximately 1.1% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 22nd largest holding. Harvest Portfolios Group Inc. owned about 0.05% of Medtronic worth $61,900,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MDT. Corundum Trust Company INC bought a new stake in shares of Medtronic in the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. acquired a new position in Medtronic during the third quarter valued at approximately $29,000. Delos Wealth Advisors LLC bought a new stake in Medtronic in the second quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic in the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in Medtronic in the third quarter worth $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MDT. Citigroup started coverage on shares of Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price target for the company. Royal Bank Of Canada boosted their target price on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. JPMorgan Chase & Co. dropped their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Daiwa Securities Group boosted their price objective on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Finally, William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average target price of $110.84.

Medtronic Stock Up 0.6%

NYSE:MDT opened at $97.60 on Friday. The stock has a 50-day simple moving average of $98.93 and a 200 day simple moving average of $96.86. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a market cap of $125.31 billion, a PE ratio of 27.19, a PEG ratio of 2.44 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).